Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide vs Placebo in T2DM on Sulfonylurea
NCT01769378Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jan 2013; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01769378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769378.